ES2367081T3 - Procedimiento para la replicación de virus de la gripe en cultivo celular y los virus de la gripe que pueden obtenerse por el procedimiento. - Google Patents
Procedimiento para la replicación de virus de la gripe en cultivo celular y los virus de la gripe que pueden obtenerse por el procedimiento. Download PDFInfo
- Publication number
- ES2367081T3 ES2367081T3 ES05075182T ES05075182T ES2367081T3 ES 2367081 T3 ES2367081 T3 ES 2367081T3 ES 05075182 T ES05075182 T ES 05075182T ES 05075182 T ES05075182 T ES 05075182T ES 2367081 T3 ES2367081 T3 ES 2367081T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- viruses
- influenza
- infection
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 238000004113 cell culture Methods 0.000 title claims abstract description 35
- 230000010076 replication Effects 0.000 title claims abstract description 22
- 241000700605 Viruses Species 0.000 title claims description 49
- 210000004027 cell Anatomy 0.000 claims abstract description 91
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 60
- 208000015181 infectious disease Diseases 0.000 claims abstract description 39
- 229960005486 vaccine Drugs 0.000 claims abstract description 39
- 230000029812 viral genome replication Effects 0.000 claims abstract description 14
- 108091005804 Peptidases Proteins 0.000 claims abstract description 10
- 239000004365 Protease Substances 0.000 claims abstract description 10
- 239000001963 growth medium Substances 0.000 claims abstract description 8
- 241001465754 Metazoa Species 0.000 claims abstract description 7
- 238000002955 isolation Methods 0.000 claims abstract description 7
- 238000009472 formulation Methods 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 210000004748 cultured cell Anatomy 0.000 claims abstract description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 14
- 102000004142 Trypsin Human genes 0.000 claims description 13
- 108090000631 Trypsin Proteins 0.000 claims description 13
- 239000012588 trypsin Substances 0.000 claims description 13
- 239000000725 suspension Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 5
- 102000012479 Serine Proteases Human genes 0.000 claims description 4
- 108010022999 Serine Proteases Proteins 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012679 serum free medium Substances 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 description 15
- 239000002609 medium Substances 0.000 description 13
- 230000003472 neutralizing effect Effects 0.000 description 13
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 238000004448 titration Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- 101710154606 Hemagglutinin Proteins 0.000 description 8
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 8
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 8
- 101710176177 Protein A56 Proteins 0.000 description 8
- 239000000185 hemagglutinin Substances 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 102000035195 Peptidases Human genes 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 6
- 238000012770 revaccination Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 5
- 208000037797 influenza A Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 231100000111 LD50 Toxicity 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 229960003971 influenza vaccine Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 241001500351 Influenzavirus A Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- ZGNLFUXWZJGETL-YUSKDDKASA-N (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium Chemical compound N[C@@H](C\[N+]([O-])=N\O)C(O)=O ZGNLFUXWZJGETL-YUSKDDKASA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 101710205768 50S ribosomal protein L34, chloroplastic Proteins 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001440741 CHER virus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- MLFKVJCWGUZWNV-UHFFFAOYSA-N L-alanosine Natural products OC(=O)C(N)CN(O)N=O MLFKVJCWGUZWNV-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229950005033 alanosine Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000001492 haemagglutinating effect Effects 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19612967 | 1996-04-01 | ||
| DE19612967A DE19612967A1 (de) | 1996-04-01 | 1996-04-01 | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2367081T3 true ES2367081T3 (es) | 2011-10-28 |
Family
ID=7790127
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05075182T Expired - Lifetime ES2367081T3 (es) | 1996-04-01 | 1997-04-01 | Procedimiento para la replicación de virus de la gripe en cultivo celular y los virus de la gripe que pueden obtenerse por el procedimiento. |
| ES09011476T Expired - Lifetime ES2435726T3 (es) | 1996-04-01 | 1997-04-01 | Procedimiento para la replicación de virus de la gripe en cultivo celular y los virus de la gripe que pueden obtenerse por el procedimiento |
| ES97915628T Expired - Lifetime ES2236799T5 (es) | 1996-04-01 | 1997-04-01 | Procedimientos de replicación de virus de influenza en cultivo celular y virus de influenza obtenibles por el procedimiento |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09011476T Expired - Lifetime ES2435726T3 (es) | 1996-04-01 | 1997-04-01 | Procedimiento para la replicación de virus de la gripe en cultivo celular y los virus de la gripe que pueden obtenerse por el procedimiento |
| ES97915628T Expired - Lifetime ES2236799T5 (es) | 1996-04-01 | 1997-04-01 | Procedimientos de replicación de virus de influenza en cultivo celular y virus de influenza obtenibles por el procedimiento |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20030119183A1 (enExample) |
| EP (3) | EP2172543B1 (enExample) |
| JP (6) | JP4447054B2 (enExample) |
| AT (2) | ATE288479T1 (enExample) |
| CA (1) | CA2250078C (enExample) |
| DE (3) | DE19612967A1 (enExample) |
| DK (2) | DK0891420T4 (enExample) |
| ES (3) | ES2367081T3 (enExample) |
| LU (1) | LU91381I2 (enExample) |
| NL (1) | NL300307I1 (enExample) |
| PT (2) | PT891420E (enExample) |
| WO (1) | WO1997037001A1 (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| JP2001521737A (ja) * | 1997-10-31 | 2001-11-13 | メルク エンド カムパニー インコーポレーテッド | 回転瓶内の水痘感染細胞培養物の混合増進方法 |
| EP1027425A4 (en) * | 1997-10-31 | 2006-04-19 | Merck & Co Inc | METHOD FOR IMPROVED MIXING IN ROLLER BOTTLES |
| FR2775601B1 (fr) * | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| AU2001236042B9 (en) | 2000-03-03 | 2006-06-29 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
| DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| CN1287770C (zh) * | 2001-11-19 | 2006-12-06 | 贝克顿迪肯森公司 | 颗粒型的药物组合物 |
| US20060019375A1 (en) * | 2002-09-16 | 2006-01-26 | Josef Seidl | Device for culturing cells, particularly human or animal cells |
| DE50211123D1 (de) | 2002-09-16 | 2007-12-06 | Pan Biotech Gmbh | Verfahren zur kultivierung von zellen, insbesondere menschlicher oder tierischer zellen |
| MXPA05005306A (es) | 2003-06-20 | 2005-10-26 | Microbix Biosystems Inc | Mejoramientos en la produccion de virus. |
| EP1722815A1 (en) | 2004-03-09 | 2006-11-22 | Chiron Corporation | Influenza virus vaccines |
| NZ551640A (en) * | 2004-05-20 | 2010-05-28 | Id Biomedical Corp | Process for the production of an influenza vaccine |
| EP2811027A1 (en) | 2004-05-21 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for RSV and PIV vaccines |
| EP2179744B1 (en) * | 2004-09-09 | 2010-12-01 | Novartis Vaccines and Diagnostics GmbH | Decreasing potential latrogenic risks associated with influenza vaccines |
| US7510719B2 (en) | 2004-12-08 | 2009-03-31 | Medimmune, Llc | Methods of producing influenza vaccine compositions |
| CA2592120A1 (en) | 2004-12-23 | 2006-07-06 | Medimmune Vaccines, Inc. | Non-tumorigenic mdck cell line for propagating viruses |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| PL2301572T3 (pl) | 2005-11-01 | 2015-02-27 | Novartis Influenza Vaccines Marburg Gmbh | Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego |
| US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| EP3714900A1 (en) * | 2005-11-04 | 2020-09-30 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| EP2368573A3 (en) | 2005-11-04 | 2013-05-01 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| US20110180430A1 (en) | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
| BRPI0618254A2 (pt) | 2005-11-04 | 2011-08-23 | Novartis Vaccines & Diagnostic | emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido |
| NZ567978A (en) | 2005-11-04 | 2011-09-30 | Novartis Vaccines & Diagnostic | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| BR122019013216B8 (pt) | 2006-01-27 | 2021-07-27 | Seqirus Uk Ltd | ensaio imunológico para análise de uma vacina contra influenza |
| WO2007110776A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
| JP2009532352A (ja) | 2006-03-31 | 2009-09-10 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ワクチンのための高力価組み換えインフルエンザ・ウィルス |
| WO2007132763A1 (ja) * | 2006-05-11 | 2007-11-22 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | インフルエンザウイルスの増殖方法 |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| EA200970271A1 (ru) | 2006-09-11 | 2010-02-26 | Новартис Аг | Получение вакцин против вируса гриппа без использования куриных эмбрионов |
| KR20140075022A (ko) | 2006-09-15 | 2014-06-18 | 메디뮨 엘엘씨 | 높은 역가로 바이러스 증식을 지원하는 ｍｄｃｋ 세포주 및 이를 이용한 생물반응기 공정 |
| SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| MX2009011899A (es) | 2007-05-04 | 2010-03-30 | Baxter Int | Perfil de temperatura de dos pasos para la propagacion de virus. |
| WO2008156778A2 (en) | 2007-06-18 | 2008-12-24 | Tokiko Watanabe | Influenza m2 protein mutant viruses as live influenza attenuated vaccines |
| ES2393162T3 (es) | 2007-06-27 | 2012-12-19 | Novartis Ag | Vacunas antigripales con un contenido reducido de aditivos |
| ES2535101T3 (es) | 2008-03-18 | 2015-05-05 | Novartis Ag | Mejoras en la preparación de antígenos en vacuna de virus de la gripe |
| US8202726B2 (en) | 2008-09-24 | 2012-06-19 | Medimmune, Llc | Methods for cultivating cells, propagating and purifying viruses |
| JP2012517416A (ja) | 2009-02-10 | 2012-08-02 | ノバルティス アーゲー | 増加した量のｈ３抗原を含むインフルエンザワクチン |
| AU2010212547B2 (en) | 2009-02-10 | 2015-03-12 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
| AU2010212550B2 (en) | 2009-02-10 | 2016-03-10 | Seqirus UK Limited | Influenza vaccines with reduced amounts of squalene |
| CN102548577A (zh) | 2009-04-27 | 2012-07-04 | 诺华有限公司 | 用于抵抗流感的佐剂疫苗 |
| ES2394797T3 (es) | 2009-05-21 | 2013-02-05 | Novartis Ag | Genética inversa usando promotores no endógenos de pol l |
| WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
| CN104862335A (zh) | 2009-07-31 | 2015-08-26 | 诺华股份有限公司 | 反向遗传系统 |
| SG178904A1 (en) | 2009-09-10 | 2012-04-27 | Novartis Ag | Combination vaccines against respiratory tract diseases |
| EP2491117B2 (en) | 2009-10-20 | 2017-06-28 | Novartis AG | Improved reverse genetics methods for virus rescue |
| ES2813347T3 (es) | 2009-10-26 | 2021-03-23 | Wisconsin Alumni Res Found | Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero |
| US20120309056A1 (en) | 2010-02-04 | 2012-12-06 | Leon Arnaud | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| US20130203151A1 (en) | 2010-04-26 | 2013-08-08 | Scott Balsitis | Production of alphavirus replicon particles in packaging cells |
| WO2011145081A1 (en) | 2010-05-21 | 2011-11-24 | Novartis Ag | Influenza virus reassortment method |
| KR102471356B1 (ko) | 2010-06-01 | 2022-11-28 | 노파르티스 아게 | 동결건조하지 않는 인플루엔자 백신 항원의 농축 |
| JP5976639B2 (ja) | 2010-06-01 | 2016-08-23 | ノバルティス アーゲー | インフルエンザワクチン抗原の濃縮および凍結乾燥 |
| CA2808965C (en) | 2010-08-20 | 2020-01-07 | Novartis Ag | Soluble needle arrays for delivery of influenza vaccines |
| BR112013008700B8 (pt) | 2010-10-11 | 2022-10-04 | Novartis Ag | Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante |
| PL2667892T3 (pl) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | Schemat szczepień przeciwko rsv |
| WO2012122625A1 (en) | 2011-03-14 | 2012-09-20 | National Research Council Of Canada | Method of viral production in cells |
| EP2747778B1 (en) | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
| BR112014008694A2 (pt) | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
| US20140348863A1 (en) | 2011-10-12 | 2014-11-27 | Alessia Bianchi | Cmv antigens and uses thereof |
| CA2852857A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
| WO2013087945A2 (en) | 2012-03-02 | 2013-06-20 | Novartis Ag | Influenza virus reassortment |
| RU2599496C2 (ru) | 2012-03-06 | 2016-10-10 | Круселл Холланд Б.В. | Улучшенная вакцинация против гриппа |
| US20150161359A1 (en) | 2012-06-04 | 2015-06-11 | Novartis Ag | Methods for safety testing |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| KR20150110494A (ko) | 2012-12-03 | 2015-10-02 | 노파르티스 아게 | 재배열 인플루엔자 a 바이러스 |
| BR112015021880A2 (pt) | 2013-03-13 | 2017-09-26 | Novartis Ag | rearranjo de vírus influenza b |
| EP2801372A3 (en) | 2013-05-10 | 2015-02-18 | Novartis AG | Avoiding narcolepsy risk in influenza vaccines |
| DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
| DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
| US10329537B2 (en) | 2013-06-06 | 2019-06-25 | Seqirus UK Limited | Influenza virus reassortment |
| AU2014290203B2 (en) | 2013-07-15 | 2020-12-24 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AR102548A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso |
| MA40920A (fr) | 2014-11-07 | 2017-09-12 | Takeda Vaccines Inc | Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| KR20180035807A (ko) | 2015-06-26 | 2018-04-06 | 세퀴러스 유케이 리미티드 | 항원적으로 매치된 인플루엔자 백신 |
| US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| HUE060924T2 (hu) | 2015-07-07 | 2023-04-28 | Seqirus Uk Ltd | Influenza elleni hatásosság vizsgálata |
| US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
| US11197926B2 (en) | 2017-10-25 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| CN111526885A (zh) | 2017-11-03 | 2020-08-11 | 武田疫苗股份有限公司 | 寨卡疫苗和免疫原性组合物及其使用方法 |
| WO2020033527A2 (en) | 2018-08-07 | 2020-02-13 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| WO2020041311A1 (en) | 2018-08-20 | 2020-02-27 | Wisconsin Alumni Research Foundation | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein |
| WO2020167432A2 (en) | 2019-01-23 | 2020-08-20 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| MX2021011913A (es) | 2019-05-08 | 2021-12-15 | Takeda Vaccines Inc | Composiciones de virus inactivado y formulaciones de vacunas contra el zika. |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| BR112022009545A2 (pt) | 2019-11-18 | 2022-10-11 | Seqirus Pty Ltd | Método para produzir vírus influenza recombinantes |
| WO2021150874A1 (en) | 2020-01-24 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized na |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| KR102444684B1 (ko) * | 2020-04-29 | 2022-09-16 | 에스케이바이오사이언스(주) | 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법 |
| WO2023154043A1 (en) | 2022-02-09 | 2023-08-17 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1278075B (de) * | 1964-06-22 | 1968-09-19 | Norden Lab Inc | Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen |
| US4064232A (en) * | 1974-01-14 | 1977-12-20 | Sandoz Ltd. | Process for isolating the immunogenic components of influenza viruses |
| US4500513A (en) * | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
| CA1122527A (en) * | 1979-05-15 | 1982-04-27 | Karen K. Brown | Influenza vaccine production in liquid cell culture |
| USRE33164E (en) * | 1979-05-15 | 1990-02-13 | Mobay Corporation | Influenza vaccine production in liquid cell culture |
| US5013663A (en) * | 1983-06-15 | 1991-05-07 | American Home Products Corporation | Canine corona virus vaccine |
| US4783411A (en) * | 1984-10-22 | 1988-11-08 | Janis Gabliks | Influenza-A virus vaccine from fish cell cultures |
| US5762939A (en) * | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| US5824536A (en) * | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
| US5753489A (en) * | 1994-11-10 | 1998-05-19 | Immuno Ag | Method for producing viruses and vaccines in serum-free culture |
| US5756341A (en) * | 1994-11-10 | 1998-05-26 | Immuno Ag | Method for controlling the infectivity of viruses |
| US5646033A (en) * | 1994-11-30 | 1997-07-08 | Dyncorp | African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines |
| DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| US6514502B1 (en) * | 1999-01-26 | 2003-02-04 | Schering-Plough Veterinary Corporation | Propagation of bovine cononavirus in chinese hamster ovary cells |
-
1996
- 1996-04-01 DE DE19612967A patent/DE19612967A1/de not_active Withdrawn
-
1997
- 1997-04-01 ES ES05075182T patent/ES2367081T3/es not_active Expired - Lifetime
- 1997-04-01 AT AT97915628T patent/ATE288479T1/de active
- 1997-04-01 DK DK97915628.8T patent/DK0891420T4/da active
- 1997-04-01 ES ES09011476T patent/ES2435726T3/es not_active Expired - Lifetime
- 1997-04-01 JP JP53509097A patent/JP4447054B2/ja not_active Expired - Fee Related
- 1997-04-01 DE DE69732407.9T patent/DE69732407T3/de not_active Expired - Lifetime
- 1997-04-01 EP EP09011476.0A patent/EP2172543B1/en not_active Revoked
- 1997-04-01 EP EP05075182A patent/EP1526172B1/en not_active Expired - Lifetime
- 1997-04-01 DK DK05075182.5T patent/DK1526172T3/da active
- 1997-04-01 EP EP97915628.8A patent/EP0891420B2/en not_active Expired - Lifetime
- 1997-04-01 WO PCT/IB1997/000404 patent/WO1997037001A1/en not_active Ceased
- 1997-04-01 PT PT97915628T patent/PT891420E/pt unknown
- 1997-04-01 AT AT05075182T patent/ATE513905T1/de active
- 1997-04-01 ES ES97915628T patent/ES2236799T5/es not_active Expired - Lifetime
- 1997-04-01 DE DE122007000082C patent/DE122007000082I1/de active Pending
- 1997-04-01 PT PT05075182T patent/PT1526172E/pt unknown
- 1997-04-01 CA CA002250078A patent/CA2250078C/en not_active Expired - Lifetime
-
2002
- 2002-09-16 US US10/245,037 patent/US20030119183A1/en not_active Abandoned
-
2006
- 2006-07-10 JP JP2006189769A patent/JP2006296437A/ja not_active Withdrawn
- 2006-11-03 US US11/592,336 patent/US20070117131A1/en not_active Abandoned
-
2007
- 2007-11-28 NL NL300307C patent/NL300307I1/nl unknown
- 2007-11-30 LU LU91381C patent/LU91381I2/fr unknown
-
2008
- 2008-06-27 JP JP2008169656A patent/JP2008245659A/ja not_active Withdrawn
-
2010
- 2010-09-03 JP JP2010198362A patent/JP5264843B2/ja not_active Expired - Lifetime
-
2011
- 2011-07-15 JP JP2011157202A patent/JP2011212020A/ja not_active Withdrawn
-
2013
- 2013-02-28 JP JP2013039239A patent/JP2013116124A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2367081T3 (es) | Procedimiento para la replicación de virus de la gripe en cultivo celular y los virus de la gripe que pueden obtenerse por el procedimiento. | |
| ES2352638T3 (es) | Células animales y procedimientos de replicación del virus de la gripe. | |
| HK1142093B (en) | Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process | |
| HK1075467B (en) | Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process | |
| CA2250714C (en) | Animal cells and processes for the replication of influenza viruses | |
| HK1019233B (en) | Animal cells and processes for the replication of influenza viruses | |
| HK1152546A (en) | Animal cells and processes for the replication of influenza viruses |